“Abnormal Retinal Reflectivity To Short-Wavelength Light In Type 2 Idiopathic Macular Telangiectasia.”. Retina 38 Suppl 1. Retina: S79-S88. doi:10.1097/IAE.0000000000001728.
. 2018. “Characteristics Of Pigmented Lesions In Type 2 Idiopathic Macular Telangiectasia.”. Retina 38 Suppl 1. Retina: S43-S50. doi:10.1097/IAE.0000000000001842.
. 2018. “Correlation Of Clinical And Structural Progression With Visual Acuity Loss In Macular Telangiectasia Type 2: Mactel Project Report No. 6-The Mactel Research Group.”. Retina 38 Suppl 1. Retina: S8-S13. doi:10.1097/IAE.0000000000001697.
. 2018. “Correlation Of Structural And Functional Outcome Measures In A Phase One Trial Of Ciliary Neurotrophic Factor In Type 2 Idiopathic Macular Telangiectasia.”. Retina 38 Suppl 1. Retina: S27-S32. doi:10.1097/IAE.0000000000001706.
. 2018. “Longitudinal Correlation Of Ellipsoid Zone Loss And Functional Loss In Macular Telangiectasia Type 2.”. Retina 38 Suppl 1. Retina: S20-S26. doi:10.1097/IAE.0000000000001715.
. 2018. “Potential Effects Of Hormone Therapy In Type 2 Idiopathic Macular Telangiectasia.”. Ophthalmic Res 60 (1). Ophthalmic Res: 38-42. doi:10.1159/000479932.
. 2018. “Ciliary Neurotrophic Factor For Macular Telangiectasia Type 2: Results From A Phase 1 Safety Trial.”. Am J Ophthalmol 159 (4). Am J Ophthalmol: 659-666.e1. doi:10.1016/j.ajo.2014.12.013.
. 2015. “Multimodal Imaging In Type 2 Idiopathic Macular Telangiectasia.”. Retina 35 (4). Retina: 742-9. doi:10.1097/IAE.0000000000000365.
. 2015. “Progression Of Vision Loss In Macular Telangiectasia Type 2.”. Invest Ophthalmol Vis Sci 56 (6). Invest Ophthalmol Vis Sci: 3905-12. doi:10.1167/iovs.15-16915.
. 2015. “Associations Between Autofluorescence Abnormalities And Visual Acuity In Idiopathic Macular Telangiectasia Type 2: Mactel Project Report Number 5.”. Retina 34 (8). Retina: 1630-6. doi:10.1097/IAE.0000000000000110.
. 2014. “Agreement Between Time-Domain And Spectral-Domain Optical Coherence Tomography In The Assessment Of Macular Thickness In Patients With Idiopathic Macular Telangiectasia Type 2.”. Ophthalmologica 230 (3). Ophthalmologica: 144-50. doi:10.1159/000353455.
. 2013. “Is Indocyanine Green Angiography Useful For The Diagnosis Of Macular Telangiectasia Type 2?”. Br J Ophthalmol 97 (7). Br J Ophthalmol: 946-8. doi:10.1136/bjophthalmol-2013-303118.
. 2013. “Medical Characteristics Of Patients With Macular Telangiectasia Type 2 (Mactel Type 2) Mactel Project Report No. 3.”. Ophthalmic Epidemiol 20 (2). Ophthalmic Epidemiol: 109-13. doi:10.3109/09286586.2013.766757.
. 2013. “"en Face" Oct Imaging Of The Is/os Junction Line In Type 2 Idiopathic Macular Telangiectasia.”. Invest Ophthalmol Vis Sci 53 (10). Invest Ophthalmol Vis Sci: 6145-52. doi:10.1167/iovs.12-10580.
. 2012. “Identification Of A Potential Susceptibility Locus For Macular Telangiectasia Type 2.”. Plos One 7 (8). Plos One: e24268. doi:10.1371/journal.pone.0024268.
. 2012. “The Is/os Junction Layer In The Natural History Of Type 2 Idiopathic Macular Telangiectasia.”. Invest Ophthalmol Vis Sci 53 (12). Invest Ophthalmol Vis Sci: 7889-95. doi:10.1167/iovs.12-10765.
. 2012. “Retinal Crystals In Type 2 Idiopathic Macular Telangiectasia.”. Ophthalmology 118 (12). Ophthalmology: 2461-7. doi:10.1016/j.ophtha.2011.05.022.
. 2011. “Baseline Characteristics Of Participants In The Natural History Study Of Macular Telangiectasia (Mactel) Mactel Project Report No. 2.”. Ophthalmic Epidemiol 17 (1). Ophthalmic Epidemiol: 66-73. doi:10.3109/09286580903450361.
. 2010. “The National Eye Institute Visual Function Questionnaire In The Macular Telangiectasia (Mactel) Project.”. Invest Ophthalmol Vis Sci 49 (10). Invest Ophthalmol Vis Sci: 4340-6. doi:10.1167/iovs.08-1749.
. 2008.